Drugs.com - Clinical Trials

Nipocalimab Granted U.S. FDA Priority Review for the Treatment of Generalized Myasthenia Gravis

SPRING HOUSE, Pa., (January 9, 2025) – Johnson & Johnson (NYSE: JNJ) today announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the U.S. Food and Drug Administration (FDA) for the...

Feb 9, 2025 - 21:44
 0
Nipocalimab Granted U.S. FDA Priority Review for the Treatment of Generalized Myasthenia Gravis
SPRING HOUSE, Pa., (January 9, 2025) – Johnson & Johnson (NYSE: JNJ) today announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the U.S. Food and Drug Administration (FDA) for the...
Read More

Tags:

Previous Article

Research and Pipeline Research Pfizer’s Sasanlimab in Combination with BCG Impro...

Next Article

Johnson & Johnson’s Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fas...

Related Posts

Humanetics Corporation Announces Positive Phase 2 Clinical Trial Results in COVID-19 Study Aimed at Improving Pulmonary Function

Humanetics Corporation Announces Positive Phase 2 Clini...

Feb 9, 2025  0

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease

Annovis Announces First Patients Entered into Pivotal P...

Feb 9, 2025  0

Boehringer Provides Update on Iclepertin Phase III Program in Schizophrenia

Boehringer Provides Update on Iclepertin Phase III Prog...

Feb 9, 2025  0